<DOC>
	<DOCNO>NCT00817271</DOCNO>
	<brief_summary>The purpose study evaluate response Glucagon versus spontaneous hormonal response low blood sugar level T2DM Patients treat AZD1656 Metformin</brief_summary>
	<brief_title>To Evaluate Response Glucagon During Hypoglycemia</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>type II diabetes patient , female non childbearing potential T2DM diagnosis confirm Cpeptide &gt; 0.3nmol/L glutamic acid decarboxylate ( GAD ) antibodies enrolment ( screen ) Treatment metformin alone total daily dose le 1 000 mg . Stable glycaemic control indicate unchanged treatment within 3 month prior enrolment History ischemic heart disease , symptomatic heart failure , stroke , transitory ischemic attack symptomatic peripheral vascular disease Signs diabetic proliferative retinopathy diabetic maculopathy , screen ophthalmological examination within 3 month start study Participating another clinical study last 30 day prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Type II Diabetes</keyword>
	<keyword>Counter-regulatory response</keyword>
	<keyword>Hypoglycemia</keyword>
</DOC>